Gain Therapeutics (NASDAQ:GANX) Stock Rating Reaffirmed as “Buy” by HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $8.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 379.04% from the company’s previous close.

GANX has been the subject of several other reports. BTIG Research reissued a “buy” rating and issued a $5.00 price objective on shares of Gain Therapeutics in a research note on Tuesday, August 11th. Wall Street Zen raised shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, June 21st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Friday, September 4th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.67.

Gain Therapeutics Trading Down 1.2%

GANX stock opened at $1.67 on Monday. Gain Therapeutics has a 12-month low of $1.53 and a 12-month high of $4.34. The business’s 50-day moving average is $1.83 and its 200 day moving average is $1.83. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.02. The stock has a market cap of $72.88 million, a price-to-earnings ratio of -3.34 and a beta of 0.19.

Gain Therapeutics (NASDAQ:GANX) last announced its earnings results on Tuesday, August 11th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. On average, sell-side analysts anticipate that Gain Therapeutics will post -0.5 EPS for the current fiscal year.

Institutional Trading of Gain Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of GANX. Potomac Capital Management Inc. purchased a new position in shares of Gain Therapeutics during the 4th quarter worth $3,252,000. GSA Capital Partners LLP acquired a new position in shares of Gain Therapeutics during the 2nd quarter valued at about $1,283,000. BlackRock Inc. purchased a new stake in shares of Gain Therapeutics in the second quarter valued at about $558,000. Squarepoint Ops LLC acquired a new stake in Gain Therapeutics during the second quarter worth about $277,000. Finally, Apollon Wealth Management LLC increased its position in Gain Therapeutics by 33.7% during the first quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock worth $51,000 after purchasing an additional 6,675 shares during the last quarter. 11.97% of the stock is owned by institutional investors and hedge funds.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc is a clinical-stage biotechnology company developing small-molecule therapies for neurodegenerative diseases and lysosomal storage disorders. Its research focuses on correcting the activity of misfolded or dysfunctional lysosomal enzymes, which are implicated in conditions involving the accumulation of toxic cellular material.

The company uses a structure-based drug discovery platform designed to identify previously unrecognized binding sites on disease-related proteins.